Estimated survival at 7 years for 553 patients treated with imatinib as initial therapy in the IRIS study. The upper curve shows survival if only CML-related deaths are considered (94%) and the lower curve shows survival taking account of deaths from all causes (86%).
 Reprinted with permission from O’Brien SG et al. Blood. 2008;112:76a.¹⁰